O-GlcNAcylated RALY Contributes to Hepatocellular Carcinoma Cells Proliferation by Regulating USP22 mRNA Nuclear Export
International Journal of Biological Sciences · 2024 · 20 (9) · 3675-3690
DOI: 10.7150/ijbs.97397 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Biological Sciences, 2024. Verfasst von Shiwei Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Southeast University, Nanjing 210009, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Cell Proliferation, Ubiquitin Thiolesterase. Die Arbeit wurde bisher 13-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is one of the most prevalent and deadly tumors; however, its pathogenic mechanism remains largely elusive. In-depth researches are needed to reveal the expression regulatory mechanisms and functions of the RNA-binding protein RALY in HCC. Here, we identify RALY as a highly expressed oncogenic factor that affects HCC cells proliferation both in vitro and in vivo. O-GlcNAcylation of RALY at Ser176 enhances its stability by protecting RALY from TRIM27-mediated ubiquitination, thus maintaining hyper-expression of the RALY protein. Mechanistically, RALY interacts with USP22 messenger RNA, as revealed by RNA immunoprecipitation, to increase their cytoplasmic localization and protein expression, thereby promoting the proliferation of HCC cells. Furthermore, we develop a novel RALY protein degrader based on peptide proteolysis-targeting chimeras, named RALY-PROTAC, which we chemically synthesize by linking a RALY-targeting peptide with the E3 ubiquitin ligase recruitment ligand pomalidomide. In conclusion, our findings demonstrate a novel mechanism by which O-GlcNAcylation/RALY/USP22 mRNA axis aggravates HCC cells proliferation. RALY-PROTACs as degraders of the RALY protein exhibit potential as therapeutic drugs for RALY-overexpressing HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Southeast University, Nanjing 210009, China.
- Hepatopancreatobiliary Center, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, China.
Zitieren
APA
Liu, S., Lv, Q., Mao, X., Dong, H., Xu, W., Du, X., Jia, W., Feng, K., Zhang, J., & Zhang, Y. (2024). O-GlcNAcylated RALY Contributes to Hepatocellular Carcinoma Cells Proliferation by Regulating USP22 mRNA Nuclear Export. International Journal of Biological Sciences, 20(9), 3675-3690. https://doi.org/10.7150/ijbs.97397
Vancouver
Liu S, Lv Q, Mao X, Dong H, Xu W, Du X, et al. O-GlcNAcylated RALY Contributes to Hepatocellular Carcinoma Cells Proliferation by Regulating USP22 mRNA Nuclear Export. International Journal of Biological Sciences. 2024;20(9):3675-3690. doi:10.7150/ijbs.97397
BibTeX
@article{Liu2024,
author = {Liu, Shiwei and Lv, Qingpeng and Mao, Xinyu and Dong, Hui and Xu, Wenjing and Du, Xuanlong and Jia, Weilu and Feng, Kun and Zhang, Jiaqi and Zhang, Yewei},
title = {O-GlcNAcylated RALY Contributes to Hepatocellular Carcinoma Cells Proliferation by Regulating USP22 mRNA Nuclear Export},
journal = {International Journal of Biological Sciences},
year = {2024},
volume = {20},
number = {9},
pages = {3675--3690},
doi = {10.7150/ijbs.97397}
}
EUVIMED